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Summary A phase study of temozolomide administered orally once a day, on 5 consecutive days, between 500 and 1200 mg m-2 per 28-
day cycle was performed. Children were stratified according to priorcraniospinal irradiation or nitrosoureatherapy. Sixteen of 20 patients who
had not received prior craniospinal irradiation or nitrosourea therapy were evaluable. Myelosuppression was dose limiting, with Common
Toxicity Criteria (CTC) grade 4 thrombocytopenia occurring in one of six patients receiving 1000 mg m-2 per cycle, and two of four patients
treated at 1200 mg in-2 per cycle. Therefore, the maximum-tolerated dose (MTD) was 1000 mg m-2 per cycle. The MTD was not defined for
children with priorcraniospinal irradiation because of poor recruitment. Plasma pharmacokinetic analyses showed temozolomide to be rapidly
absorbed and eliminated, with linear increases in peak plasma concentrations and systemic exposure with increasing dose. Responses (CR
and PR) were seen in two out of five patients with high-grade astrocytomas, and one patient had stable disease. One of ten patients with
diffuse intrinsic brain stem glioma achieved a long-term partial response, and a further two patients had stable disease. Therefore, the dose
recommended for phase II studies in patients who have not received prior craniospinal irradiation or nitrosoureas is 1000 mg n-2 per cycle.
Further evaluation in diffuse intrinsic brain stem gliomas and other high-grade astrocytomas is warranted.
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Temozolomide (3.4-dihydro-3methN14-oxoimidazo-[5.1.d]-1.2.3.
5-tetrazin-8-carboximide: SCH 52365) is one of a number of
imidazotetrazine derivatives developed by Stevens et al (1987).
The lead compound in this series. mitozolomide. demonstrated
anti-tumour activity in patients with a variety of tumours.
including malignant melanoma (Gundersen et al. 1987). However.
the further development of mitozolomide was precluded because
of severe and unpredictable myelosuppression. Temozolomide. an
analogue of mitozolomide. was subsequently selected for clinical
development because of its demonstrated anti-tumour activitv
and more favourable toxicity profile in preclinical testing (Stevens
et al. 1987).
Temozolomide undergoes spontaneous degradation at physiolog-
ical pH to the active moiety. monomethvl triazenoimidazole carbox-
amide (MTIC: Fiaure 1: Stevens et al. 1987). The cytotoxicity of
MTIC is thought to result from the reactive methylation ofguanine.
primarily at the 0( position and to a lesser extent the N- position
(Catapano et al. 1987). Resistance to temozolomide-mediated cyto-
toxicity correlates both with the expression ofa specific DNA repair
protein. 06-methylguanine DNA methyltransferase (MGMT).
which removes (iY6-methylguarine adducts byt self-inactivation
(Catapano et al. 1987) and the presence of a deficiency in the
mismatch repair pathway (Wedge et al. 1996: Liu et al. 1996).
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In preclinical testing. temozolomide was found to have schedule-
dependent anti-tumour activity against a broad spectrum of murine
tusmonrs in vivo. including leukaemias. lymphomas and solid
tumours (Stevens et al. 1987). The initial phase I study in adults used
a Cancer Research Campaign (CRC) formulation of temozolomide
(CCRG 81045: Newlands et al. 1992). Temozolomide was initially
studied with a single-dose schedule and demonstrated linearpharma-
cokinetics with increasing dose and myelosuppression as the dose-
limiting toxicity. No anti-tumour activity was seen in the 51 patients
studied (Newlands et al. 1992). However, when temozolomide was
given orally over 5 consecutive days. activity was observed in
patients with high-grade astrocytomas (HGA). malignant melanoma
and in one patient with mycosis fungoides. As in the single-dose
schedule. myelosuppression was found to be dose limiting (New-
lands et al. 1992). The recommended phase HI dose was 750 mO M-'
forthe first treatment cycle. followed by 1000 mg m-' forsubsequent
cycles if there was no dose-limiting myelosuppression on the first
cycle. Phase H studies with the CRC formulation of temozolomide
have subsequently shown activity in phase H trials with HGA
(O'Reilly et al. 1993) and metastatic melanoma (Bleehen et al. 1995)
but not with low-grade non-Hodgkin's lymphoma (Woll et al. 1995).
Forclinical development in the USA. a phase I trial oftemozolomide
(NSC 362856). which differs from the CRC preparation with regard
to inert ingredients. has also demonstrated dose-limiting myelosup-
pression (Dhodapkaret al. 1997). Subsequently. a newformulation of
temozolomide. SCH 52365. has beendevelopedby Schering-Plough.
SCH 52365 has been re-evaluated in phase I studies in adult patients.
confirming similartoxicity findings and maximum-tolerated dose for
this formulation (Brada et al. 1995: Reidenberg et al. 1996).
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Figure 1 The chemical structures of temozolomide (SCH 52365) and the active cytotoxic species MTIC
High-grade astrocytomas are relatively common paediatric
brain tumours that have a poor prognosis and against which there
is a paucity of active anti-tumour agents. As preliminary studies
with temozolomide in adults have demonstrated a tolerable safety
profile and promising clinical activity. particularly in patients with
HGA. evaluation of temozolomide in children with these tumours
is required. The primary aims ofthis multicentre phase I trial were
to characterize the safety profile and to determine the dose-
limiting toxicity (DLT). maximum-tolerated dose (MTD) and
pharmacokinetics of temozolomide (SCH 52365) administered
orally. once daily for 5 days. in paediatric patients with advanced
cancers not involving the bone marrow. Patients were stratified
according to whether or not they had received prior craniospinal
irradiation (CSI) or nitrosourea therapy.
PATIENTS AND METHODS
Patient demography, diagnosis and prior therapy
The study was open from March 1994 to March 1996. Patients
aged less than 18 years. with histologically proven malignancy.
for whom no conventional therapies were available to offer a
reasonable hope of cure or significant palliation were eligible.
Neuroradiological imaging alone was accepted for diffuse intrinsic
brain stem gliomas. Patients were required to have a Common
Toxicity Criteria (CTC) performance status of0. 1 or 2 (except for
patients with brain stem tumours who were allowed a performance
status of3). One patient with a brain stem glioma and performance
status of4 was entered and was not evaluable because ofdeath due
to disease progression in the first cycle. No nitrosourea or mito-
mycin C therapy was allowed within 6 weeks. and no other
chemotherapy or radiotherapy was to have been received within 4
weeks of the first dose of temozolomide. The following patients
were not eligible to enter the study: patients who had a malignancy
that involved the bone marrow: those who were a poormedical risk
because of systemic disease: HIV-positive patients: those who had
received prior allogeneic or autologous bone marrow transplanta-
tion: those who had received a prior peripheral stem cell transplan-
tation and those with previous or concurrent malignancies. Eligible
patients were stratified according to whether they had not (Arn A)
or had (Arm B) received prior CSI ornitrosourea therapy.
Twenty-eight patients were entered into the study. The patient
characteristics for each arm of the study are shown in Table 1.
Twenty patients (16 evaluable) were entered into Arm A. Four
patients were not evaluable for toxicity as two patients died of
disease progression during the first treatment cycle, one patient
was regarded as non-evaluable because of non-compliance. and
one patient was unable to swallow the capsules. Eight patients
were entered into Arm B. and six of these were evaluable. One
patient progressed during the first cycle and did not complete the
safety evaluation for that cycle. and one patient died of disease
progression during the first treatment cycle. The majority of
patients enrolled into the study had a diagnosis of a primary
central nervous system tumour. Fifteen of 20 patients in Arm A
had eitheradiffuse intrinsic brain stem glioma or high-grade astro-
cytoma Six of the eight patients in Arm B had a diagnosis of
primitive neuroectodermal tumour. Three patients in Arm A were
enrolled with performance status scores of 3 or 4. and all these
patients had a diagnosis of brain stem glioma. Seven of the 20
patients in Arm A had received prior chemotherapy (three patients
had received doxorubicin: four cisplatin: three carboplatin: four
Tabe 1 The patient demography, diagnosis, evaluablity and pnor therapy
for Arn A and Arm B
Tmnozobmide phase I stud
patwd ch_ i acte1-1 -_ C SArm A Arm B
Total number entered 20 8
Total number evaluable for toxicity 16 6
Sex
Male 8 4
Female 12 4
Age (years)
Mean 9 9
Median 9 8
Range 4-18 4-17
CTC performance status at entry
0 4 4
1 7 3
2 6 1
3 2 -
4 1 -
Diagnoss
Brain stem glioma 10
High-grade astrocytoma 5
Haemangiopeitcoma 1
Rhabdomyosarcoma 1 1
Chondrosarcoma 1 -
Osteogenic sarcoma 1 -
Pancreatic neuroendocrie tumour 1 -
Primitive neuroectodermal tumour - 6
Ependymoma - 1
Prortherapy
Ch erapy 7 7
Radiotherapya 16 8
Surgery 8 6
aladiotherapy for Arm B -craniospinal irradiation. Radiotherapy for Arm A
directed at sites other tan the craniospinal axis.
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vincristine: three ifosfamide: two actinomycin-D: three etoposide:
one cyclophosphamide and one thiotepa). Eight patients had prior
surgery. and 16 radiotherapy (excluding craniospinal irradiation).
Seven of the eight patients in Arm B had received prior
chemotherapy. and all had undergone surgery and radiotherapy
Laboratory investigations were performed within 14 days
before the first dose oftemozolomide to ensure adequate haemato-
logical (Hb > 9 g dl-'. neutrophil count > 1 x 1091-1 platelet count
> 100 x 10 1-1). renal (serum creatinine < 1.5 x the upper limit of
laboratory normal for age) and hepatic (serum total bilirubin
within the upper limit oflaboratory normal. aspartate transaminase
(AST) or alanine transaminase (ALT) < two times the upper limit
of laboratory normal) function. Patients were expected to have a
life expectancy of at least 9 weeks. Written. informed and
witnessed consent was obtained from all patients or their parents.
The study was approved by the relevant local ethics committee.
Study design
Administration anddrug supply
Patients were entered into the study from seven participating
centres. Registration. requests for temozolomide. adverse event
reporting and notification of withdrawal from study was coordi-
nated by the UKCCSG data centre. A pre-registration procedure.
whereby referring physicians were advised of the availability of a
place within a treatment cohort. was introduced as it became
necessary to freeze recruitment if a full cohort of patients had not
been evaluated for toxicity in the first treatment cycle. The study
was performed to full Good Clinical Practice guidelines (CPMP
Working Party. 1990) and was sponsored. monitored and reported
by Schering-Plough. As well as baseline haernatological and bio-
chemical investigations. a full physical examination. electrocardio-
gram. urinalysis and radiological imaging ofany tumour sites were
performed within 14 days ofthe first dose oftemozolomide.
Temozolomide (SCH 52365) was manufactured in the USA by
Schering-Plough (Kenilworth. NJ. USA) and was supplied in
20 mg or 100 mg gelatin capsules by the CRC Formulation
Unit. Department of Pharmaceutical Sciences. University of
Strathclyde. Glasgow. UK. Temozolomide was administered daily
for 5 consecutive days. Patients fasted for 8 h before. and for 2 h
after. each dose of temozolomide. Antiemetics were administered
after the first episode of emesis and were then allowed on a
prophylactic basis. Treatment cycles were repeated every 28 days.
provided there was recovery from toxicity. All responding
patients. or those with stable disease. continued on therapy with
temozolomide for 1 year. unless disease progression was observed.
Patient evaluation
Patient review. physical examination and measurement of the full
blood count and serum concentrations of urea, creatinine. elec-
trolytes. calcium. phosphate. magnesium. glucose. total bilirubin.
total protein. albumin. alanine aminotransferase. alkaline phos-
phatase were carried out weekly for the first two cycles. Patients
were then reviewed at the end of each treatment cycle and the
above assessments repeated. Radiological evaluation of tumour
sites was performed at the end of each of the first two treatment
cycles. and then after alternate cycles. Patients were evaluable for
response ifthey received 5 days oftemozolomide and were evalu-
able for toxicity if they survived for at least a further 23 days.
Tumour responses were graded according to WHO guidelines
(WHO. 1979). Complete response (CR) was defined as the
complete disappearance of all detectable disease. Partial response
(PR) was defined as greater than 50% reduction in the sum of the
products ofthe two largest perpendicular diameters ofall measur-
able lesions. Stable disease (SD) was defined as a less than 50%
reduction but not greater than 25% increase in the sum ofthe prod-
ucts of the two largest perpendicular diameters of all measurable
lesions. All assessments of response and stable disease were
determined by two observations not less than 4 weeks apart.
Progressive disease (PD) was defined as a greater than 25%
increase in the sum ofthe products ofthe two largest perpendicular
diameters of all measurable lesions. or the appearance ofany new
lesions. Radiological imaging before therapy. after two courses
and at time of maximal response was reviewed centrally and
independently by two experienced paediatric neuroradiologists.
The pathology ofall responding patients was reviewed centrally.
Dose escalation
Temozolomide dosage was based on body surface area, which was
calculated according to the formula recommended by Mosteller
(1987):
Height (cm) x weight (kg)
3600
The dose given was the nearest that the capsules allowed. with
approximation increasing the dose if necessary. Arm A was esca-
lated through four dose levels: 500. 800. 1000 and 1200 ma m-'
per cycle. Arm B was dose escalated from 500 to 600 mg m-2 per
cycle before this arm of the trial was closed. Patients were
recruited in cohorts of three per dose level. and dose-limiting
toxicity was defined from the safety profile of cycle 1 for each
patient. No within-patient dose escalations were allowed.
Definition ofDLTandMTD
Toxicity was evaluated according to the Common Toxicity Criteria
(CTC). A dose-limiting toxicity was defined during the first 28
days after the first daily dose ofSCH 52365 as follows:
1. CTC grade 4 neutropenia that did not resolve within 7 days.
grade 4 anaemia orgrade 3 thrombocytopenia that did not
resolve within 7 days. CTC grade 4 thrombocytopenia ofany
duration was also taken to be dose limiting.
2. Other CTC grade 3 or 4 toxicity except forgrade 3 nausea and
vomiting, grade 3 fever (in the absence ofinfection) and grade
3 hepatic toxicity that returned to a minimum ofgrade 1 before
the commencement ofthe next treatment cycle.
When DLT was encountered in one patient ofa cohort ofthree. a
maximum of three additional patients were treated at that level. If
DLT was not observed with the additional patients. then the next
dose level was entered. The MTD was defined as that dose level
immediately below the dose level at which a minimum of two
patients in a cohort of three to six patients experienced DLT. A
maximum of one out of six patients could experience DLT at the
MTDdose level. Atotal ofsix patients weretreatedatthe MTDdose
level to fully assess toxicity. This strategy allowed the MTID to be
estimated using a minimum numberofpatients (Kom et al. 1994).
Pharmacokinetics
Pharmacokinetic evaluations were performed during cycle 1 for at
least two evaluable patients per dose level. Blood samples were
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Table 2 Neutropenia occurmng in children receiving SCH 52365
CTC Grade
Dose level Evaluable 0 1 2 3 4
(mg M-2 courses
per cycle) n
500 21 18 3 - - -
600 4 3 1 - - -
800 25a 23 2 -
1000 16: 6 4 3 - 6
1200 8 1 1 2 1 3
aIncludes three cydes as dose reduction after DLT. "includes four cycles as
dose reduction after DLT.
Table 3 Thrombocytopenia occurring in children receiving SCH 52365
CTC grade
Dose level Evaluable 0 1 2 3 4
(mng M-2 courses
per cycle) n
500 21 21 - - - -
600 4 4 - - - -
800 25a 22 - 1 2 -
1000 16: 8 - 3 - 5
1200 8 1 0 1 2 4
alcudes three cycles as dose reduction after DLT. Includes four cycles as
dose reduction after DLT.
drawn into pre-chilled syringes immediately before each dailx
dose of SCH 52365 and at the following times after the fifth oral
SCH 52365 dose: 10. 20. 30. 60. 90. 120. 150. 180. 240 and
360 min. and 8. 12 and 24 h. The blood samples were placed in
pre-chilled heparinized tubes. kept on ice and centrifuged at 4°C
within 30 min of collection. A 2-ml volume of plasma was trans-
ferred to a plastic tube containing 0.1 ml of8.5% (%,/v) phosphoric
acid. The acidified plasma sample was then briefl vortexed and
placed into labelled plastic tubes and stored at -'0'C until
analysis. The exact time of dosing and withdrawal of pharmaco-
kinetic samples was noted. Urine A-as also collected at baseline
(0 h) and 0-4. 4-8 and 8-24 h after the fifth dose of SCH 52365.
The collected urine was kept below pH 4 by the addition of 8.5%7
(w/v) phosphoric acid. At the end of each collecting period. the
total volume and pH ofthe urine was recorded. and a20-ml aliquot
ofwell-mixed urine frozen at -20 C until analysis.
Measurement oftemozolomide in plasma samples
The reagents used for sample preparation and analysis included
acetonitrile. ethyl acetate. o-phosphoric acid 8.5%7 (w/x-) and water
(Fisher. Pittsburgh. PA. USA). Stock solutions of temozolomide
(200 jig ml-' ) and the internal standard (IS) ethazolastone
(100 igo ml-' ) were prepared in 20% (v/v) methanol in water
containing 0.4% (v/v glacial acetic acid. Spiking solutions for the
plasma calibration curve standards and quality control samples
were prepared by dilution with 20% v/X methanol in water
containing 0.4% (v/v) glacial acetic acid. A 1.0PCg ml' working
solution of the IS was prepared in water containing 200 pil of
glacial acetic acid per 100 ml of water. The eight standards
required to construct the standard cursve 0.1-20pj ml-') and at
least six or nine quality control (QC) samples (0.2. 1.5. 15 jg ml-)
were made up in acidified analyte-free human plasma (120 il of
8.5% (/vlx) phosphoric acid per 4 ml ofhuman plasma).
Patient plasma samples were allowed to thaw in a water bath
at room temperature. and 0.5-ml aliquots pipetted into separate
16 x 125-mm screw cap glass culture tubes. This was followed bv
the addition of 0.5 ml of the IS working solution and all samples
were acidified by the addition of 50 il of 1 N hydrochloric acid.
Five millilitres of ethvl acetate was then added to each tube. and
the contents mixed in a shaker for 10 min. The samples were
centrifuged at 3000g for 5 min. and the organic layer transferred
to a separate 16 x 100-mm culture lass tube by freezing the
aqueous laver in a drx ice bath. The organic layer was evaporated
to drvness at 45 C under air. The residue was then reconstituted in
0.3 ml of mobile phase ( 10:90 (X/X) acetonitrile and 0.1%c
(c/I) glacial acetic). The samples were analysed by high-
performance liquid chromatography (HPLC) using a Waters 501
pump. a TOSOH 6080 autoinjector. a Waters Lambda Max
481 LV detector and an Ultrasphere ODS analytical column
(15 cm x 4.6 mm. 5 jim particle size). The chromatographic
conditions were: LIV. 316 nm: injection volume. 20 il: temozolo-
mide retention time. 2.5-3.5 min: IS retention time. 5.0-6.5 min:
HPLC flow rate. 1 ml min-'.
The equation for each calibration curve Aas calculated by linear
regression VAith 1/v weighting. using the peak height ratio of
temozolomide to the internal standard for each calibration curve
standard. The concentration of temozolomide in each plasma
sample was determined using the slope and intercept values from
the calibration curve equation. The louVer limit of quantification
for temozolomide w'as 0.1jIg ml-'.
Measurement oftemozolomide in urine samples
The same HPLC methodology w-as used for measurement of SCH
52365 in patient urine samples waith the follow-ing differences:
mobile phase. 7:93 (v/v) methanol and 0.09% (-/v) glacial acetic
acid: standard curve. 1-200jg ml-': QCs. 2. 15 and 150jg ml-':
SCH 52365 retention time. approximately 5 min: IS retention time.
approximately 14 min: lower limit ofquantification. 1 jgo ml-'.
For the plasma and urine SCH 52365 assays. the accuracy.
precision and inter/intraday variabilities were < 15%c.
Pharmacokinetic data
The following pharmacokinetic parameters A-ere summarized for
each patient:
Cog Maximum plasma concentration.
To
MaN Time ofmaximum plasma concentration.
al! Elimination half-life. This was calculated as 0.693/K.
K Terminal phase rate constant. This was calculated as
the negative slope ofthe log-linear terminal portion of
the plasma concentration - time curve using linear
regression.
AUC(tf) Area under the concentration vs time curve (AUC)
from time 0 to last measurable concentration [Ctfi].
This was calculated using the linear trapezoidal
method.
AUC( I) AUC from time 0 to infinity. This was calculated bx
extrapolating the AUC (tf) to infinitv usine the
formnula AUC (1) = AUC (tf) + C (tf)/K. where C (tf)
is the estimated concentration determined from linear
regression at time tf.
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Table 4 Most commonly encountered non-haematogical adverse events
for children receiving SCH 52365. The values refer to the percentage of
children who experienced each adverse event
Adverse event CTC grade 1-2 CTC grade 3
(%) (%)
Vomiting 79 4
Headache 32 -
Nausea 28 -
Upper respiratory tract infection 17 -
Constipation 21 -
Haematoma 14 -
Ataxia 10 4
Pain 8 4
Diarrhoea 4 -
Fatigue 4 -
Epistaxis 4 -
Petechiae 4 -
Catheter site infection 4 -
C[JF Apparent total body clearance (absolute and
normalized for surface area). This was calculated as
CLUF = Dose/AUC (I).
CLR Renal clearance. This was calculated using the
equation CIR = Ae (0-24 h)/AUC (0-24 h). where
Ae (0-24 h) is the amount oftemozolomide excreted
in the urine from time 0 to 24 h.
Vdarea/F Apparent volume ofdistribution (absolute and
normalized for surface area). This was calculated
using the equation Vdarea/F = [Dose/AUC(I)YIK
F Fraction oforal dose absorbed (assumed to be 1.0)
RESULTS
Toxicity
Myelosuppression was found to be dose limiting. Details of the
neutropenia and thrombocytopenia encountered in this study are
shown in Tables 2 and 3 respectively. For Arm A of the study.
dose-limiting haematological toxicity was encountered at
1000 mg m-2 per cycle and 1200 mg m-2 per cycle, with minimal
toxicity observed in earlier dose levels. Thrombocytopenia was
dose limiting. with grade 4 toxicity occurring in one ofsix patients
during the first course at the 1000 mg m-2 dose level, and two of
four patients during the first course at the 1200 mg m 2dose level.
In addition, two of these patients, one at 1000 mg m-2 per cycle
and one at 1200 mg m-2 dose level, experienced grade 4
neutropenia of 7 days' duration. Grade 3 or 4 myelosuppression
was not observed before day 20. The nadir platelet count occurred
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Figure 2 SCH 52365 plasma pharmacoinetic profiles for day 5 of cycle 1
are shown for each dose level; 500, 600, 800,1000 and 1200mg mr per
cycle of Arm A and Arm B combined. The values represent the mean plasma
SCH 52365 concentration for each time point
at days 22. 23 and 23 for the three patients with dose-limiting
thrombocytopenia. In these three patients. the platelet count recov-
ered to > 100 x 109/1-' by days 29. 32 and 65. The nadir neutrophil
count occurred at days 29 and 24 and recovered to > 1 x l09/1-1
by days 43 and 27. Two of the six evaluable patients at the
1000 Mmgm2 per cycle dose level had received prior chemo-
therapy. and dose-limiting thrombocytopenia was observed in one
ofthese patients (who had received prior vincristine and cisplatin).
Two ofthe four evaluable patients entered at the 1200 mg m-2per
cycle dose level had received prior chemotherapy. and dose-
limiting thrombocytopenia was observed in one of these patients
(who had received prior thiotepa). The three patients experiencing
dose-limiting myleosuppression during cycle 1 had a 20% reduc-
tion in their temozolomide dosage for cycle 2. In addition. one
further patient at the 1200 mg m-2 dose level experienced grade 4
neutropenia and grade 4 thrombocytopenia in cycle 2 and
continued temozolomide after a dose reduction. Grade 3 anaemia
was also observed in those patients experiencing dose-limiting
myelosuppression. No haematological toxicity was observed in
Arm B. except for one patient who had been misrandomized and
who had received the highest dose of Arn A (1200 mg mu2 per
cycle). This patient experienced CTC grade 4 thrombocytopenia
and neutropenia, and grade 3 anaemia The MTD oftemozolomide
was therefore defined as 1000 mg m-2 per cycle in patients who
had not received prior spinal irradiation or nitrosoureas.
The main non-haematologcal toxicities associated with temozolo-
mide in Arm A were nausea. vomiting, headache, constipation and
ataxia(Table4). Nausea andvomiting were common but were easily
controlled with standard antiemetic therapy. The majority of non-
haematological adverse events were CTC grade 1 or 2 (Table 5).
Table 5 Pharmacokinetic analyses for children receiving SCH 52365. The results are expressed as mean ± % cv
Dose level Number of C. T_, AUC (tf) AUC (1) tu CL/F CL/F(in2) Vdarea/F VdarealF(i2)
(Mg M-2 percycle) patens (ig Mil) (h) (pg h ml-) (bg hnil) (h) (ml minn-) (nl mimn..2) I) (l me
500 5 9.48 (42) 1.27 (75) 23 (11) 24 (11) 1.7 (11) 68.6 (42) 73 (15) 10.5 (55) 11.0 (24)
600 3 9.35 (24) 1.4 (36) 27 (19) 28 (17) 1.7 (9) 97 (36) 77 (18) 13.9 (29) 11.0 (9)
800 3 11.1 (32) 1.9 (53) 37 (2) 37 (2) 1.7 (8) 68.(9) 72 (2) 10.4 (16) 10.9 (10)
1000 5 14.6 (24) 1.9 (40) 48 (17) 49 (17) 1.7 (4) 71 (29) 72 (16) 10.5 (30) 10.6 (19)
1200 3 17 (22) 1.7 (46) 45 (16) 45 (16) 1.4 (22) 117 (35) 93 (14) 13.6 (43) 10.7 (11)
British Journal ofCancer (1998) 78(5), 652-661 0 CancerResearch Campaign 1996Phase I trial oftemozolomide (SCH52365) in children 657
Table 6 Patients with high-grade astrocytoma or diffuse intrinsic brain stem gliorna with either stable disease (SD), partial response (PR) or complete
renission (CR) on Arm A
Dose level Tumour No. of Response Mainum TImeto Progressionfre
(mg m-2 per cycle) type courses after two response maximum free
courses response intel
(wek) (wek)
1 500 High-grade astrocytoma 13 SD CR 52 71a
2 800 High-grade asbocytoma 6 PR PR 16 27
3 1200 Highrade astroytoma 4 SD SD 16
4 800 Brain stem glioma 13 SD PRb 32 54
6 1000 Brain stem glioma 7 SD SD 27
7 1200 Brain stem glioma 5 SD SD 20
aRelapse ofastrocytoma in contralateral, non-irradiated cerebral hemiphere. bSCH 52365 commenced 24 days aftercompletion ofradiothey.
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Figure 3 The relationship between dose administered (mg rnr2 per cycle)
and day 5 peak plasma concentration of SCH 52365 (jg ml-') for Arm A and
Arm B combined
Pharmacokiwnetics
Temozolomide plasma pharmacokinetics were evaluable in 19
patients, and the plasma pharmacokinetic analyses for these
patients are shown in Table 5. Pharmacokinetic profiles for each
dose level (both arms combined) are shown in Figure 2 and demon-
strate the rapid absorption and elimination oforal temozolomide in
this patient population. A significant linear relationship was found
between the peak plasma concentration of temozolomide and
increasing dose of temozolomide (r' = 0.36. P < 0.01; Figure 3).
Similarly, a significant linear relationship was found for the AUC
(I) and increasing doses of temozolomide (r2 = 0.69. P < 0.0001:
Figure 4). Interpatient variability for systemic exposure (AUC) to
temozolomide was small at each dose level, with a coefficient of
variation of less than 20% (Figure 4 and Table 6). Temozolomide
was undetectable before administration on each of the 5-day
courses of treatment. On day 5, maximum plasma temozolomide
concentrations were achieved approximately 1.5 h afterdosing. and
the mean to:1 ranged from 1.4 to 1.9 h. Individual apparent total
body clearance (CLEF) ranged from 56.1 to 107 ml min-' m-' and
was dose independent, assuming that temozolomide has a bio-
availability of 100% in this paediatric population. The individual
Vdarea/F ranged from 8.27 to 15.41 m-2. Pharmacokinetic compar-
isons between the two arms ofthe study were only possible for the
500 mg m-' per cycle dose level. and similar results for each arm
were obtained.
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Figure 4 The relationship between dose administered (mg m-2 per cycle)
and Fe day 5 AUC (I) of SCH 52365 (1g9 h mMt) for Arm A and Arm B
combined
Plasma pharmacokinetics were measured in four of the six
patients who encountered grade 3 or 4 haematological toxicity.
Three patients achieved an AUC of> 50 jg h mlF. and twoofthese
patients experienced dose-limiting thrombocytopenia. However.
one patient at the 800 mg m-' percycle dose level experienced only
grade 2 thrombocytopenia with an AUC of62 lag h ml-'.
Urinary excretion was measured in 13 patients. Urinary
recovery of temozolomide ranged from 5% to 15% of the dose
administered over the 24-h collection period. Individual renal
clearances ranged from 2.7 to 10.7 ml min-' M-2 and was dose
independent. Because temozolomide undergoes chemical degrada-
tion in the body at physiological pH. the limited renal clearance.
compared with the apparent total body clearance (CU/F) was
expected.
Efficacy
Three of 15 patients with high-grade astrocytomas and diffuse
intrinsic brain stem gliomas responded (one CR and two PR). In
addition, three patients had stable disease of 6, 6 and 4 months
duration (Table 6). One ofthe ten patients with brain stem glioma
had a partial response and was withdrawn from the study in
response after 13 cycles of treatment. This patient. a 4-year-old
girl with a grade 3 astrocytoma. progressed during radiotherapy
(54 Gy). as documented on computerized tomography (CT) scan.
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FIgure 5 Response to ftwrapy with SCH 52365 as imaged by CT scan.
A was taken at progression, 24 days after completxio of radioherapy and
emergency surgery. Bdemonstrateste response after two courses of
temozoloride (stable disease) and C demonstrates fe maimmal response
(partial response at28weeks). The paint was a4-year-old gir, with a
diffuse intrinsic brain stem gioma (grade 3 astrocytoma), who progressed
despite radio erapy
Debulking surgery was required in the 5th week of the 6-week
course of radiotherapy. Radiotherapy was completed 24 days
before commencing temozolomide, and the radiological response
is demonstrated in Figure 5. Afterone course oftemozolomide. the
tumourremained unchanged in size, but showed less enhancement
than at baseline. After two courses, the tumour appeared necrotic.
with a 12.5% reduction in the product oftwo maximal perpendic-
ular diameters. A maximum response of a 81% reduction was
observed after 32 weeks of therapy. Clinical improvement was
noted during the first cycle of therapy and was maintained.
allowing the gradual withdrawal of dexamethasone by week 10.
The patient received 1 year of therapy in total. In two further
patients with diffuse intrinsic brain stem gliomas, stable disease
was observed for 20 and 27 weeks. Five patients progressed after
two courses, and one patient progressed after one course of
therapy. A further patient died on the 14th day ofcycle 1 because
ofdisease progression.
Two of five patients with high-grade astrocytoma responded
(one complete response and one partial response). An 8-year-old
girl with a grade 3 anaplastic astrocytoma progressed after radio-
therapy (54 Gy) to an unresected left cerebral hemisphere tumour.
Therapy with temozolomide was commenced 44 days after the
completion ofradiotherapy. A 30% reduction in the product ofthe
British Journal ofCancer (1998) 78(5), 652-661
B
0 CancerResearch Campaign 1996Phase I trial oftemozolomide (SCH52365) in children 659
c
Figure 6 Response to therapy with SCH 52365 as imaged by CT scan.
A was taken at relapse, B after two courses of SCH 52365 (partal response)
and C at the time of maxinal response (at 17 weeks), in a 9-year-old girl with
a glooblastoma, which recurred 62 weeks after total excision and radiotherapy
two maximal perpendicular diameters ofthe tumour was observed
after two cycles oftherapy, and no tumour was detectable after 52
weeks of therapy. During this time. the patient showed continued
improvement in her right-sided hemiplegia, and therapy with
dexamethasone was withdrawn by week 14. The patient relapsed
with disease in the contralateral (non-irradiated) cerebral hemi-
sphere 5 months after temozolomide was discontinued.
Another patient. a 9-year-old girl with a right cerebral giant-cell
glioblastoma. had a total resection and radiotherapy (54 Gy) 14
months before her relapse. After two courses of therapy with
temozolomide, a 70% reduction in the product ofthe two maximal
perpendicular diameters of the tumour was observed, and the
maximum response of a 81% reduction was observed after 16
weeks (Figure 6). This patient became asymptomatic during the
course ofhertherapy with temozolomide. allowing the withdrawal
of dexamethasone by week 8. The partial response lasted for 20
weeks. One further patient had stable disease lasting 4 months.
All patients with primitive neuroectodermal tumours (six).
ependymoma (one). rhabdomyosarcoma (one), chondrosarcoma
(one). osteogenic sarcoma (one). pancreatic neuroendocrine
tumour (one) and haemangiopericytoma (one) progressed after
one or two courses oftherapy.
DISCUSSION
This phase I study has determined the dose-limiting toxicities. MTD
and pharmacokinetics of oral temozolomide in children who have
not received prior therapy with CSI or nitrosoureas. Although the
MTD oftemozolomide given orally for 5 days has been established
in adults (Newlands et al. 1992: Brada et al. 1995: Reidenberg et al.
British Journal ofCancer (1998) 78(5), 652-661
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1996) it was necessary to define the MTD of temozolomide in
children, as the MTD of anti-cancer agents can be markedly
different between children and adults (Marsoni et al, 1985).
As previous studies in children have shown that the MT) of
anti-cancer agents can be influenced by the intensity of prior
therapy (Pearson et al, 1994), patients were initially stratified
according to whether or not they had received prior CSI or
nitrosourea therapy. However, entry to the prior CSI/nitrosourea
arm of the study was closed after the initial two dose levels
because ofpoor recruitment
Because, at the beginning ofthis phase I study, SCH 52365 had
not been fully evaluated in an adult phase I trial, the starting dose
level for both arms of the trial was 50% of the adult MTD estab-
fished with the original CRC formulation (Newlands et al, 1992).
The finding of thrombocytopenia as the dose-limiting toxicity in
this study is in keeping with the original adult phase I trial of oral
temozolomide, in which myelosuppression was found to be dose
limiting. As in the adult phase I study (Newlands et al, 1992),
thrombocytopenia occurred 20 days after the beginning ofthe first
treatment cycle and persisted for between 7 and 42 days.
Although, in this present study, dose-limiting myelosuppression
was notobservedincycle I in one patientat the 1200 mgm-2dose
level, grade 4 thrombocytopenia was observed in this patient on
subsequent courses, necessitating a dose reduction. Furthermore, a
recent phase I study of SCH 52365 in adults has also established
thrombocytopenia as the dose-limiting toxicity, with an MTD of
1000mg m-2percycle (Brada et al, 1995). The importance ofprior
therapy has also been reported, with a lower MTD reported for
patients receiving heavy prior chemotherapy (Reidenberg et al.
1996; Dhodapkar et al, 1997). For this present study, for patients
who had not received prior CSI or nitosoureas, no relationship
between the intensity of prior therapy and dose-limiting toxicity
could be determined.
The other main toxicities associated with temozolomide in this
paediatric phase I study were nausea and vomiting. These symp-
toms were usually limited to day 1 of the first cycle and were
easily controlled with standard antiemetic therapy. The toxicities
of headache observed in Arm A and Arm B, and ataxia, pain and
constipation in Arm B were thought to be due to the patients'
underlying CNS tumours. or to treatment for constipation. Oral
temozolomide was very well tolerated, with all but one child able
to swallow the capsules. However, the necessity of swallowing
whole capsules meant that very young children could not be
entered into the study. There were no deaths attributed to temo-
zolomide-related toxicity.
The results of the pharmacokinetic analyses ofthis phase I study
were compatible with the findings from the adult phase'l studies
(Newlands et al, 1992: Schering-Plough Research Institute. 1996),
with rapid absorption, rapid elimination, no accumulation on day 5
and a linear increase in peak plasma concentration and systemic
exposure with increasing dose. Overall, the plasma concentrations
oftemozolomide in paediatric patients were approximately 15-30%
higher than those observed at similardose levels in the adult phase I
study of SCH 52365 (Brada et al. 1995; Schering-Plough Research
Institute, 1996). Similarly, systemic exposure (AUC) to temozolo-
mide was higher in paediatric patients, with an increase ofapproxi-
mately 40% compared with adult patients (Schering-Plough
Research Institute, 1996). Moreover, an important characteristic of
temozolomide is that the pharmacokinetics are reproducible in this
patient population, as demonstrated by the small interpatient vari-
ability in systemic exposure. Other pharmacokinetic parameters in
this pediatric study, i.e. T andtr,. were similar to those observed
in adults. As in the adult phase I study of SCH 52365, the urinary
clearance oftemozolomide was small compared with apparent total
body clearance. However, urinary excretion may have been underes-
tiatd 1because of the breakdown of temozolomide in the urine,
before micturition and subsequent stabilization oftemozolomide by
acidification ofthe urine.
In an adult phase II study of temozolomide in primary brain
tuinours (O'Reilly et al, 1993), major clinical improvement was
found in six out of ten evaluable patients with high-grade astrocy-
tomas who had relapsed after radiotherapy. This was accompanied
by a marked improvement in radiological appearance in five out of
ten patients. Moreover, reduction in the size of tumours was also
seen in four out of seven patients with unirradiated astrocytomas
(O'Reilly et al, 1993), confirming the suggestion of activity
against HGA observed in the original phase I study (Newlands et
al, 1992). Activity in this paediatric study has been demonstrated
in patients with high-grade astrocytoma and brain stem glioma,
with measurable and confirmed responses (CR or PR) found in
two out offive cases ofhigh-grade astrocytoma, and one out often
cases of diffuse intrinsic brain stem glioma. Although temozolo-
mide was commenced 24 days after the completion of radio-
therapy for the responding patient with a brain stem glioma, it was
felt that the clinical and radiological responses seen were attribut-
able to therapy with this agent Response assessment in patients
with CNS tumours is known to be difficult; however, only neuro-
radiological responses were considered in this study. All tumour
sizes were measured independently by the local and two central
radiologists to ensure a non-biased conclusion. Maximal responses
were seen after more than two cycles of therapy in these three
patients, in whom the greatest response occurred at 16, 32 and 52
weeks. Two patients with stable disease after two courses subse-
quently achieved a CR and a PR.
The cytotoxicity oftemozolomide is thought to relate primarily
to methylation ofguanine at the 06 position, and this DNA lesion
is repaired by the protein 06-alkylguanine DNA alkyltransferase
(Catapano et al, 1987). The finding that this repair protein cannot
be detected in 22% of primary brain tumours (Citron et al, 1991)
and that the levels ofMGMT in human tumourcells correlate with
temozolomide cytotoxicity (Wedge et al, 1996) may prove to be
clinically important observations. Indeed, rapid and sustained
depletion of MGMT occurs in adult patients with a 200 mg m-2
bolus dose of temozolomide followed by a twice-daily oral
regimen for 5 days (Gerson et al, 1996).
As the prognosis for both high-grade astrocytoma and brain
stem glioma in children is poorwith current therapy, phase H eval-
uation oftemozolomide is warranted for both ofthese conditions.
Consideration should also be given to evaluating activity oftemo-
zolomide in other poor-risk tumours, such as neuroblastoma. in
which dacarbazine is known to be active.
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